REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's

For Alzheimer's Agitation, Promising News from Rexulti

Rexulti Works for Agitation in Alzheimer's, Despite Risks, Says

Mark Oldham on X: I had no clue they were going for this

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

agitation that may happen with dementia due to Alzheimer's disease

Rexulti (brexpiprazole) is filed in Japan for Alzheimer's

Antipsychotic Drug Reduces Alzheimer's-Associated Agitation

Bioxcel shares plunge on FDA warning letter despite promising data